System biology analysis to develop diagnostic biomarkers, monitoring pathological indexes, and novel therapeutic approaches for immune targeting based on maggot bioactive compounds and polyphenolic cocktails in mice with gastric cancer

Meta-analyses of the relationship between five CXCL8 gene polymorphisms and overall cancer risk, and a case-control study of oral cancer

“…In addition, both miR146a rs2910164 and miR499a rs3746444 can influence the expression of CXCL8 and were associated with the development of cutaneous leishmaniasis caused by leishmania guyanensis [ 44 ]. Furthermore, Kaviani et al suggested CXCL8 was involved in key molecular mechanisms related to the promotion of inflammation and oxidative stress and subsequently the development of gastric cancer, and also was considered as cut-point druggable protein, which maybe the potential of targeting for therapeutic objective [ 45 ]. Above articles indicated SNPs from CXCL8 may be associated with the different expression of CXCL8 and status of inflammation and oxidative stress, then result in the development of cancer and be considered as a druggable protein for treatment of cancer.…”

Research on lncRNA CTBP1-DT as a potential therapeutic target to regulate cell function in colorectal cancer

“…As a new type of tumor marker, ncRNAs (lncRNAs and miRNAs) have simple detection methods and broad applications, making them a current research hotspot. In exploring tumor therapies, Elina et al demonstrated that polyphenol natural compounds and maggot larvae are novel targets for immunotherapy of gastric cancer by introducing lncRNAs and combining with systematic biological analyses [ 22 ]. A recent study also suggested that lncRNA may serve as a drug target for the complementary treatment of colorectal cancer based on sparassis latifolia and exercise [ 23 ].…”

The roles and molecular mechanisms of non-coding RNA in cancer metabolic reprogramming

“…Chemotherapy, radiation, targeted therapy and immunotherapy are the major strategies used for malignant cancers. However, the outcome of patients does not remain satisfactory due to limitations such as multi-drug resistance and tumor relapse [ 156 ]. Numerous types of research have implicated that ncRNAs may be a potential target to overcome therapeutic tolerance.…”

“…Current findings suggest that the various combinations of treatments with produced anti-PD-1, CD80-Fc, and 4-1BBL-Fc proteins reduce inhibitory signals while increasing activatory signals, potentially lowering the risk of tumor resistance and improving treatment efficacy [ 169 ]. Based on previous studies, inhibiting NEAT1, XIST, and IL-6 may be very effective for the clinical treatment of GC [ 156 , 170 ]. Recently, Elina Kaviani et.al revealed polyphenol natural compounds and maggot larvae (as sources for safe and effective bioactive compounds) can contribute to immunotherapy and chemotherapy activity as a complementary therapy via reducing the expression level of MKI67, CXCL8, IL-6/IL-6R, lncRNA XIST and NEAT1 and ultimately decreased the size and number of tumors [ 156 ].…”

“…Based on previous studies, inhibiting NEAT1, XIST, and IL-6 may be very effective for the clinical treatment of GC [ 156 , 170 ]. Recently, Elina Kaviani et.al revealed polyphenol natural compounds and maggot larvae (as sources for safe and effective bioactive compounds) can contribute to immunotherapy and chemotherapy activity as a complementary therapy via reducing the expression level of MKI67, CXCL8, IL-6/IL-6R, lncRNA XIST and NEAT1 and ultimately decreased the size and number of tumors [ 156 ]. Hence, the combination of ncRNAs and immunotherapy drugs is likely to be an effective strategy for improving immune treatment efficacy [ 167 , 168 , 171 ].…”